Title
Noninvasive Prenatal Screening (NIPS) for Fetal Chromosome Abnormalities in A General-Risk Population
Authoring Organization
Publication Month/Year
December 16, 2022
Last Updated Month/Year
August 9, 2023
Supplemental Implementation Tools
Document Type
Guideline
Country of Publication
US
Document Objectives
This workgroup aimed to develop an evidence-based clinical practice guideline for the use of noninvasive prenatal screening (NIPS) for pregnant individuals at general risk for fetal trisomy 21, trisomy 18, or trisomy 13 and to evaluate the utility of NIPS for other chromosomal disorders.
Target Patient Population
Pregnant individuals in general risk categories for chromosomal disorders
Target Provider Population
Geneticists, OBGYNs and other allied providers
Inclusion Criteria
Female, Adolescent, Adult
Health Care Settings
Ambulatory, Laboratory services, Outpatient
Intended Users
Genetics, nurse, nurse practitioner, physician, physician assistant
Scope
Assessment and screening
Diseases/Conditions (MeSH)
D006580 - Genetic Carrier Screening, D000081182 - Noninvasive Prenatal Testing
Keywords
Down syndrome, NIPS, noninvasive prenatal screening, Cell-free DNA
Source Citation
Dungan JS, Klugman S, Darilek S, Malinowski J, Akkari YMN, Monaghan KG, Erwin A, Best RG; ACMG Board of Directors. Electronic address: documents@acmg.net. Noninvasive prenatal screening (NIPS) for fetal chromosome abnormalities in a general-risk population: An evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2022 Dec 13:S1098-3600(22)01004-8. doi: 10.1016/j.gim.2022.11.004. Epub ahead of print. PMID: 36524989.